Dosing & Uses
Dosage Forms & Strengths
powder for injectable solution
- 50mg/vial
- 100mg/vial
- 200mg/vial
Colorectal Cancer
Indicated in combination with infused 5-fluorouracil/leucovorin for adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor and also for treatment of advanced colorectal cancer
Advanced colorectal cancer
- Day 1: Oxaliplatin 85 mg/m² IV + leucovorin 200 mg/m² IV infused over 2 hr, THEN
- 5-FU 400 mg/m² IV bolus over 2-4 minutes, THEN
- 5-FU 600 mg/m² IV infusion in D5W (500 mL) over 22 hr
- Day 2: Same regimen WITHOUT oxaliplatin
- Repeat every 2 weeks
Adjuvant treatment for stage III colon cancer
- 12 cycles, every 2 weeks, according to the dose schedule above, for a total of 6 months
- Adjuvant use follows tumor resection
Dosage Modification
If persistent Grade 2 neuropathy, decrease dose to 75 mg/m²
If persistent Grade 3 neuropathy, consider discontinuing oxaliplatin
After recovery from grade 3/4 GI or grade 3/4 hematological toxicity: Decrease dose to 75 mg/m² , AND decrease 5-FU by 20% (300 mg/m² bolus, 500 mg/m² infusion)
After recovery from grade 3/4 GI or hematologic toxicities
- Advanced colorectal cancer: Decrease dose to 65 mg/m² , AND decrease 5-FU by 20% (300 mg/m² bolus, 500 mg/m² infusion)
- Adjuvant therapy for stage II colon cancer: Decrease dose to 75 mg/m² , AND decrease 5-FU by 20% (300 mg/m² bolus, 500 mg/m² infusion)
Renal impairment
- Exposure of unbound platinum tends to increase in renally impaired patients
- Mild-to-moderate (CrCl 30-80 mL/min): No dosage adjustment required
- Severe (CrCl <30 mL/min): Reduce starting dose to 65 mg/m²
Ovarian Cancer (Orphan)
Orphan designation for treatment of ovarian cancer
Sponsor
- Debio Pharm S.A.; Rue des Terreaux 17 CH-1000; Switzerland
Cholangiocarcinoma (Orphan)
Orphan designation for liposomal oxaliplatin for treatment of cholangiocarcinoma
Sponsor
- KC Specialty Therapeutics, LLC; 2002 West 39th Avenue; Kansas City, Arkansas 66103
Pancreatic Adenocarcinoma (Orphan)
Orphan designation for liposomal oxaliplatin for treatment of pancreatic adenocarcinoma
Sponsor
- 2 KC Specialty Therapeutics, LLC; 2002 West 39th Avenue; Kansas City, Arkansas 66103
Safety and efficacy not established
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Adverse Effects
>10%
Peripheral neuropathy (76%)
Anemia (64%)
Nausea (64%)
Fatigue (61%)
Diarrhea (46%)
Vomiting (37%)
Abdominal pain (31%)
Constipation (31%)
Thrombocytopenia (30%)
Fever (25%)
Anorexia (20%)
Leukopenia (13%)
Dyspnea (13%)
Cough (11%)
1-10%
Edema (10%)
Neutropenia (7%)
Pharyngolaryngeal dysesthesia (1-2%)
<1%
Pulmonary fibrosis
Posterior leukoencephalopathy syndrome
Frequency Not Defined
Anaphylactic-like reaction (uncommon)
Pulmonary fibrosis (uncommon)
Postmarketing Reports
Body as a whole: Angioedema, anaphylactic shock
Central and peripheral nervous system disorders: Loss of deep tendon reflexes, dysarthria, Lhermitte’s sign, cranial nerve palsies, fasciculations, convulsion, RPLS
Hearing and vestibular system disorders: Deafness
Infusion reactions/hypersensitivity: Laryngospasm
Liver and gastrointestinal system disorders: Severe diarrhea/vomiting resulting in hypokalemia, colitis (including Clostridium difficile diarrhea), metabolic acidosis; ileus; intestinal obstruction, pancreatitis; veno-occlusive disease of liver (ie, sinusoidal obstruction syndrome), perisinusoidal fibrosis which rarely may progress
Platelet, bleeding, and clotting disorders: immuno-allergic thrombocytopenia prolongation of prothrombin time and of INR in patients receiving anticoagulants
Red blood cell disorders: Hemolytic uremic syndrome, immuno-allergic hemolytic anemia
Renal disorders: Acute tubular necrosis, acute interstitial nephritis, acute renal failure
Respiratory system disorders: Pulmonary fibrosis, and other interstitial lung diseases (sometimes fatal)
Cardiovascular toxicity
Rhabdomyolysis
Septic shock
Warnings
Black Box Warnings
The drug should be administered under the supervision of an experienced cancer chemotherapy physician in a facility equipped to diagnose and manage complications
Anaphylactic-like reactions have been reported and may occur within minutes of administration. Epinephrine, corticosteroids, and antihistamines have been used to treat these symptoms
Contraindications
Hypersensitivity to oxaliplatin, other platinum compounds
Pregnancy
Cautions
Caution in renal impairment, elderly, neuropathy, neurotoxic agents
For 3-4 days, avoid contact with ice/cold food/objects, avoid breathing cold air
Avoid contact with aluminum needles or equipment
Avoid pregnancy
Pulmonary fibrosis may occur
Concomitant use with fluorouracil may increase gastrointestinal effects
Grade 3 or 4 neutropenia reported in patients with colorectal cancer treated in combination with 5-flurouracil (5-FU) and leucovorin; delay oxaliplatin therapy until neutrophils are at 1.5 x 10^9/L; withhold oxaliplatin for sepsis or septic shock; reduce dose after recovery from Grade 4 neutropenia or febrile neutropenia
Cardiovascular toxicity reported; ECG monitoring recommended if therapy initiated in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics, and electrolyte abnormalities; correct hypokalemia or hypomagnesemia prior to initiating oxaliplatin and monitor these electrolytes periodically during therapy; avoid oxaliplatin in patients with congenital long QT syndrome
Reversible posterior leukoencephalopathy syndrome (RPLS, also known as PRES, Posterior Reversible Encephalopathy Syndrome) reported in clinical trials and postmarketing experience
Rhabdomyolysis, including fatal cases reported; discontinue oxaliplatin if any signs or symptoms of rhabdomyolysis occur
Pregnancy & Lactation
Pregnancy Category: D
Lactation: not known if excreted in milk
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Platinum coordination compound that inhibits DNA synthesis; cross-links and denatures strands of DNA; disrupts DNA function by covalently binding to DNA bases
Pharmacokinetics
Peak plasma time: 2 hr
Concentration: 1.21 mcg/mL
Protein bound: >90%; platinum accumulates in RBCs
Vd: 440 L
Half-life: 391 hr
Clearance: 10.1 L/hr
Excretion: Urine (54%); feces (2%)
Dialyzable: no
Administration
IV Incompatibilities
Alkaline medications or media (eg, basic solutions of 5-FU)
IV Preparation
Reconstitute by adding 10 mL (for 50 mg vial) or 20 mL (for 100 mg vial) of SWI or D5W. Dilute required amount of reconstituted solution in an infusion solution of 250-500 mL of D5W. Do NOT use NS or chloride-containing solutions
Reconstituted solution may be refrigerated up to 24 hr at 2-8°C (36-46°F). After final dilution with 250-500 mL D5W, the shelf life is 6 hr at room temp [20-25°C (68-77°F)] or up to 24 hr under refrigeration at 2-8°C (36-46°F)
Eloxatin is not light sensitive
Do not use aluminum-containing needles or IV administration sets that may come in contact with carboplatin (aluminum can react causing precipitate formation and loss of potency)
IV Administration
Flush infusion line with D5W prior to administration of oxaliplatin or any concomitant drug
Inspect visually for particulate matter and discoloration prior to administration and discard if present
Use separate bags for oxaliplatin and leucovorin (administered through Y-site)
See adult dosing for infusion and bolus rate
Images
Patient Handout
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.